Research signals – Signal Engine

• Diffuse Large B-Cell Lymphoma - PMC — Diffuse large B-cell lymphoma
• The Revolution of Targeted Therapies in Thyroid Cancer Treatment: Present and Future Promising Anti-Cancer Drugs — Thyroid cancer
• Clinical Impact of EGFR Mutation Subtypes on Treatment Outcomes in Advanced Non-Small Cell Lung Cancer: An Austrian Real-World Study — NSCLC
• People with lung cancer have more microplastics in their lungs — Lung cancer
• Biotech Catalyst Calendar – Trial Readout Dates by Month – SPZCO — NSCLC
• Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer — Thyroid cancer
• Biomarker-Independent ADC Rina-S Advances to Phase 3 in Endometrial Cancer — Endometrial cancer
• Mount Sinai Study Finds Chemotherapy-Free Treatment Shows Promise for Some Patients With Metastatic Breast Cancer — Breast cancer
• Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology — NSCLC
• New fibroblast state reveals how lung tumors may suppress immune defenses — NSCLC
• Spatial profiling of the spleen in mouse and human myelofibrosis reveals complement‑driven immune‑stromal interactions as a therapeutic target. — Myelofibrosis
• Induction Paclitaxel-Cisplatin-Capecitabine for Nasopharyngeal Carcinoma — Nasopharyngeal carcinoma
• Modern Gastric Cancer Care: From Diagnosis to Treatment — Gastric cancer
• Hemophagocytic lymphohistiocytosis and posterior reversible encephalopathy syndrome during BRAF/MEK inhibitor therapy following immune checkpoint blockade in metastatic melanoma: a case report — Melanoma
• Evaluation of the Effects of Date Palm Leaf Extract (Phoenix dactylifera) on EGFR Gene Expression in the MDA-MB-231 Breast Cancer Cell Line — Breast cancer
• A Novel Therapeutic Approach for High‑Risk and Relapsed/Refractory Neuroblastoma: Dinutuximab Beta — Neuroblastoma
• ctDNA Detects Postsurgical Merkel Cell Recurrence — Merkel cell carcinoma
• The 25th Anniversary of Imatinib and the Evolution of Small Molecule Inhibitors — Breast cancer
• Phytochemicals Targeting Inflammatory Signaling Pathways to Combat Gastric Cancer — Gastric cancer
• Hodgkin Lymphoma – Brown Health Cancer Institute — Hodgkin lymphoma
• AstraZeneca Ends Volrustomig Trial for First-Line Metastatic NSCLC — NSCLC
• Anaplastic Large Cell Lymphoma: Overview, Subtypes of ALCL, Genetic‑Molecular Characteristics and Their Effects — Diffuse large B-cell lymphoma
• Prostate Cancer — Prostate cancer
• Dinutuximab Combination Therapy for High-Risk Neuroblastoma — Neuroblastoma
• Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer — Endometrial cancer
• Lung Cancer Clinical Trials at UCSF – 2026 — NSCLC
• Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of Recurrence‑Free Survival (RFS) and Distant Metastasis‑Free Survival (DMFS) in Patients With Completely Resected Stage IIB‑IV Melanoma — Melanoma
• Squamous Cell Carcinoma — Head and neck squamous cell carcinoma
• HER2/ERBB2 In Solid Tumors: A Practical Guide To Testing And IHC Scoring — Breast cancer
• Anal Cancer — Anal squamous cell carcinoma
• Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma — Melanoma
• Lymphoma — Diffuse large B-cell lymphoma
• Case Study: 65-Year-Old with History of Waldenstrom Macroglobulinemia — Waldenstrom macroglobulinemia
• Acute Lymphoblastic Leukemia — Acute lymphoblastic leukemia
• Mantle Cell Lymphoma — Mantle cell lymphoma
• Radiopharmaceutical therapy delays metastatic prostate cancer disease progression when given earlier — Prostate cancer
• Cemiplimab Addition to Docetaxel and Ramucirumab Trial in NSCLC — NSCLC
• Esophageal Cancer — Esophageal cancer
• Esophageal Cancer — Esophageal cancer
• Thyroid Cancer — Thyroid cancer
• Pancreatic Cancer — Pancreatic cancer
• Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) — NSCLC
• Anti‑tumor Activity of CBI‑1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI‑L Colorectal Cancer — Colorectal cancer
• Adagrasib Monotherapy and in Combination With Pembrolizumab for KRAS G12C‑Positive Non‑Small Cell Lung Cancer (NSCLC) — NSCLC
• Esophageal Cancer — Esophageal cancer
• Chronic Myeloid Leukemia — Chronic myeloid leukemia
• Stomach Cancer Clinical Trials at UCSF — Gastric cancer
• Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non‑Small Cell Lung Cancer — NSCLC
• Nasopharyngeal Cancer: Background, Relevant Anatomy, Pathogenesis — Nasopharyngeal carcinoma
• Treatment Strategies for B-Cell Acute Lymphoblastic Leukemia in Younger Patients — Acute lymphoblastic leukemia